David Planchard: Beating Durvalumab Monotherapy Post-CRT in Unresectable Stage III NSCLC

David Planchard, Thoracic Oncologist, Professor at University Paris Saclay and Head of Thoracic Cancer Group at Gustave Roussy, shared this post on LinkedIn:

“A higher-than-expected step towards beating durvalumab monotherapy post CRT unresectable stage III NSCLC…PACIFIC 9 ?

Great discussions at the ISCO meeting in Cairo !”